T3D-959 is our lead drug candidate, a ‘First-in-Class’ therapeutic designed to address the underlying metabolic and lipid dysfunction driving Alzheimer’s disease and other neurodegenerative disorders. It has the potential to slow, stop, or reverse the progression of the disease by improving brain energy metabolism and reducing neurodegeneration.